💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acarbose

CHEMBL404271 Phase 4 ได้รับการอนุมัติ Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
645.6 g/mol
LogP
-8.8
Phase
4

An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

น้ำหนักโมเลกุล

645.6000 g/mol

LogP

-8.80

TPSA

329.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

Cardiovascular Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Hepatitis C

กลไกการออกฤทธิ์

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H43NO18

                    

                    
                    

                        
HBD / HBA

                        
14 / 19

                    

                    
                    

                        
พันธะที่หมุนได้

                        
13

                    

                    
                    
                    

                        
อะตอมหนัก

                        
44

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
An oral medication that slows the digestion of carbohydrates in the intestine by blocking enzymes that break down complex sugars, resulting in a more gradual rise in blood glucose after meals. It is used alongside diet and exercise to manage type 2 diabetes and lowers after-meal blood sugar spikes without causing low blood sugar on its own. Digestive side effects such as gas and bloating are common, especially early in treatment, and tend to improve over time.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acarbose is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL404271.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9811704.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.